Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DAO | P14920 | 3/20 | 0.50 |
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.48 |
| ▸ | TKT | P29401 | 1/20 | 0.42 |
| ▸ | KDM1A | O60341 | 1/20 | 0.41 |
| ▸ | MAOA | P21397 | 1/20 | 0.41 |
| ▸ | MAOB | P27338 | 1/20 | 0.41 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.36 |
| ▸ | HTR2A | P28223 | 1/20 | 0.36 |
| ▸ | GRIN2B | Q13224 | 3/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.35 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.35 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.35 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.35 |
| ▸ | PI4KA | P42356 | 1/20 | 0.35 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.35 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.35 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.35 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL991269 | 0.89 | DAO (0.48) | DAOTRPV4TKTKDM1AMAOA | |
| SCHEMBL934644 | 0.84 | TRPV4 (0.52) | DAOTRPV4TKTKDM1AMAOA | |
| SCHEMBL264730 | 0.81 | TAAR1 (0.52) | DAOTRPV4TKTKDM1AMAOA | |
| SCHEMBL3851699 | 0.81 | DAO (0.50) | DAOTRPV4TKTKDM1AMAOA | |
| SCHEMBL28513175 | 0.81 | TRPV4 (0.48) | DAOTRPV4TKTKDM1AMAOA | |
| SCHEMBL2468426 | 0.81 | DAO (0.37) | DAOPDPK1KCNH2HTR2ATDP1 | |
| SCHEMBL694114 | 0.81 | DAO (0.50) | DAOTRPV4TKTKDM1AMAOA | |
| SCHEMBL30074791 | 0.81 | TRPV4 (0.48) | DAOTRPV4TKTKDM1AMAOA | |
| SCHEMBL19615786 | 0.81 | TRPV4 (0.53) | DAOTRPV4TKTKDM1AMAOA | |
| SCHEMBL1259004 | 0.81 | TKT (0.55) | DAOTRPV4TKTKDM1AMAOA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2017198812-A2 | PROCESS FOR THE MANUFACTURE OF 2-SUBSTITUTED-5-(1-METHYLTHIO)ALKYLPYRIDINES | SOLVAY SA (BE) | 2017-11-23 | — | — | WO | disclosed |
| US-9469641-B2 | Pyrido[3,4-B]indoles and methods of use | MEDIVATION TECHNOLOGIES, INC. (US) | 2016-10-18 | — | — | US | disclosed |
| WO-2016100940-A1 | DOPAMINE D2 RECEPTOR LIGANDS | THE BROAD INSTITUTE, INC. (US) | 2016-06-23 | — | — | WO | disclosed |
| US-9260429-B2 | Pyrido[3,4-B]indoles and methods of use | MEDIVATION TECHNOLOGIES, INC. (US) | 2016-02-16 | — | — | US | disclosed |
| EP-2274307-B1 | BRIDGED HETEROCYCLIC COMPOUNDS AND METHODS OF USE | MEDIVATION TECHNOLOGIES INC (US) | 2015-07-29 | — | — | EP | disclosed |
| US-9051314-B2 | Bridged heterocyclic compounds and methods of use | MEDIVATION TECHNOLOGIES, INC. (US) | 2015-06-09 | — | — | US | disclosed |
| US-9034869-B2 | Bridged heterocyclic compounds and methods of use | MEDIVATION TECHNOLOGIES, INC. (US) | 2015-05-19 | — | — | US | disclosed |
| US-8999977-B2 | Bridged heterocyclic compounds and methods of use | MEDIVATION TECHNOLOGIES, INC. (US) | 2015-04-07 | — | — | US | disclosed |
| US-20140024643-A1 | BRIDGED HETEROCYCLIC COMPOUNDS AND METHODS OF USE | MEDIVATION TECHNOLOGIES, INC. (US) | 2014-01-23 | — | — | US | disclosed |
| CN-103467471-A | Organic compounds | INTRA CELLULAR THERAPIES INC | 2013-12-25 | — | — | CN | disclosed |
| EP-2280968-A2 | PYRIDO [3, 4-B]INDOLES AND METHODS OF USE | Medivation Technologies, Inc. (US) | 2011-02-09 | — | — | EP | disclosed |
| EP-2274307-A1 | BRIDGED HETEROCYCLIC COMPOUNDS AND METHODS OF USE | Medivation Technologies, Inc. (US) | 2011-01-19 | — | — | EP | disclosed |
| US-20100099667-A1 | BRIDGED HETEROCYCLIC COMPOUNDS AND METHODS OF USE | MEDIVATION TECHNOLOGIES, INC. | 2010-04-22 | — | — | US | disclosed |
| US-20090270412-A1 | PYRIDO[3,4-B]INDOLES AND METHODS OF USE | MEDIVATION TECHNOLOGIES, INC. | 2009-10-29 | — | — | US | disclosed |
| WO-2009120717-A2 | PYRIDO [3, 4-B] INDOLES AND METHODS OF USE | MEDIVATION TECHNOLOGIES, INC. (US) | 2009-10-01 | — | — | WO | disclosed |
| WO-2009120720-A1 | BRIDGED HETEROCYCLIC COMPOUNDS AND METHODS OF USE | MEDIVATION TECHNOLOGIES,INC. (US) | 2009-10-01 | — | — | WO | disclosed |
| EP-2086936-A2 | PROCESS FOR THE PREPARATION OF 2-SUBSTITUTED-5-(1-ALKYLTHIO)ALKYLPYRIDINES | Dow AgroSciences LLC (US) | 2009-08-12 | — | — | EP | disclosed |
| CN-101248050-A | Organic compounds | INTRA CELLULAR THERAPIES INC (US) | 2008-08-20 | — | — | CN | disclosed |
| WO-2008066558-A2 | PROCESS FOR THE PREPARATION OF 2-SUBSTITUTED-5-(1-ALKYLTHIO)ALKYLPYRIDINES | DOW AGROSCIENCES LLC (US) | 2008-06-05 | — | — | WO | disclosed |
| CN-1918165-A | Azabicyclic heterocycles as cannabinoid receptor modulators | BRISTOL MYERS SQUIBB CO (US) | 2007-02-21 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140024643-A1 | BRIDGED HETEROCYCLIC COMPOUNDS AND METHODS OF USE | HRH4, HNMT, HTR2C | DAO 334/4885TRPV4 667/4885TKT 1595/4885 |
| US-20090270412-A1 | PYRIDO[3,4-B]INDOLES AND METHODS OF USE | HTR3B, HTR4, HTR2C | DAO 219/4885TRPV4 669/4885TKT 1481/4885 |
| US-20100099667-A1 | BRIDGED HETEROCYCLIC COMPOUNDS AND METHODS OF USE | HRH4, HNMT, HTR2C | DAO 334/4885TRPV4 667/4885TKT 1595/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.